KCNH2 and familial long QT syndrome: Candidate drugs for repurposing in LQTS should have a favorable safety profile, lack inhibition of Kv11.1 current, and achieve human plasma concentrations comparable to those effective in vitro for improving Kv11.1 trafficking.